Cost-Effectiveness of XXXX Patches for Smoking Cessation in Pregnancy: A Placebo Randomized Controlled Trial (SNAP).

@entity1 @entity2208 @entity1239 @entity600
INTRODUCTION: Smoking during pregnancy is the most important, preventable cause of adverse pregnancy outcomes including @entity2208 , @entity600 , and low birth weight with huge financial costs to the National Health Service. However, there are very few published economic evaluations of smoking cessation interventions in pregnancy and previous studies are predominantly U.S.-based and do not present incremental cost-effectiveness ratios (ICER). A number of studies have demonstrated cost-effectiveness of @entity1239 replacement therapy (NRT) in the general population, but this has yet to be tested among pregnant smokers. METHODS: A cost-effectiveness analysis was undertaken alongside the smoking, @entity1239 , and pregnancy trial to compare NRT patches plus behavioral support to behavioral support alone, for pregnant @entity1 who smoked. RESULTS: At delivery, biochemically verified quit rates were slightly higher at 9.4% in the NRT group compared to 7.6% in the control group (odds ratio = 1.26, 95% CI = 0.82-1.96), at an increased cost of around   90 per @entity1 . Higher costs in the NRT group were mainly attributable to the cost of NRT patches (mean =   46.07). The incremental cost-effectiveness ratio associated with NRT was   4,926 per quitter and a sensitivity analysis including only singleton births yielded an ICER of   4,156 per quitter. However, wide confidence intervals indicated a high level of uncertainty. CONCLUSIONS: Without a specific willingness to pay threshold, and due to high levels of statistical uncertainty, it is hard to determine the cost-effectiveness of NRT in this population. Furthermore, future research should address compliance issues, as these may dilute any potential effects of NRT, thus reducing the cost-effectiveness.
